Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year. You can read the ICAT supervisor policy here.
Full NameDr David Grieve
Centre for Experimental Medicine
Queen's University Belfast
Webpage:qub.ac.uk
Email Address:Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- cell and developmental biology/regenerative medicine
- physiology and non-communicable disease
- Medicine
- Surgery
- Pathology
- Radiology
- Sports and Exercise Medicine
- Cardiology
- Endocrinology
- Immunology
- Pharmacology
- Physiology
- Vascular Medicine
My research programme is mainly focussed on investigating mechanisms underlying cardiovascular remodelling and dysfunction, with a particular interest in the role of oxidative stress, novel peptide hormones, endothelial progenitor cells, and the influence of diabetes. My group employs a wide range of laboratory techniques, from in vivo physiology to molecular biology and tissue culture, to investigate mechanisms underlying the adaptive but ultimately detrimental changes that occur in various cardiovascular disease states and how these may be modulated for potential therapeutic benefit.
Ongoing translational research projects include:
• Endothelial Nox2 NADPH oxidase as a key driver of adverse cardiac remodelling associated with diabetes
• Influence of Nox4 NADPH oxidase on endothelial progenitor cell function and their ability to promote angiogenesis in tissue ischaemia
• Does Nox4 NADPH oxidase play a key role in direct reprogramming of fibroblasts into endothelial cells and underlie their ability to promote angiogenesis?
• Selective targeting of glucagon-like peptide-1 as a novel approach to prevent adverse cardiovascular remodelling associated with diabetes
• Identification of prognostic circulating microRNA-based markers of diabetic patient outcome after aortic valve replacement surgery